Singh Vishwadeep, Pahade Akhilesh, Mowar Ashita
Department of Anesthesiology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India.
Anesth Essays Res. 2022 Jul-Sep;16(3):353-359. doi: 10.4103/aer.aer_121_22. Epub 2022 Dec 9.
Perioperative pain management is a major challenge for anaesthesiologists. IV lidocaine and dexmedetomidine have been utilised for peri-operative pain management.
To analyse the effects of intraoperative intravenous lignocaine/dexmedetomidine on pain relief, opioid consumption, peri-operative hemodynamic and side-effect profiles/unique interactions in patients undergoing laparoscopic surgeries.
Prospective, interventional, single-centric, double-blind, randomised, active-controlled, Helsinki protocol-compliant clinical study was conducted on 90 ASA I/II class patients aged 18-60 yrs. This Patients were block-randomised to Group-L (2% Lignocaine), Group-D (dexmedetomidine) and Group C (Control/Placebo/0.9% normal saline). Hemodynamic were noted at pre-defined time frames intra-/post-operatively. Post-operative VAS score and Richmond Agitation Sedation Score monitoring was done.
Demographic parameters of were comparable. Mean intra-operative fentanyl consumption amongst the three groups were 20.5 ± 20.05 mcg, 26.5 ± 17.57 mcg and 46.83 + 21.31 mcg (Group-L, Group-D, Group-C; value Group-L vs Group-D:0.22, Group L/D vs Group C: <0.0001). Group-D exhibited the lower heart rates and MAP ( < 0.05). Extubation- First rescue analgesic phase was comparable for the Group-C and Group-L (59.17 ± 46.224 min vs 61.64 ± 53.819 min) and significantly greater in Group-D (136.07 + 55.350 min; < 0.0001).
Both Dexmedetomidine and lignocaine can be useful intra-operative pain relief adjuncts. Dexmedetomidine delayed First rescue analgesic and total analgesic consumption more than lignocaine. Dexmedetomidine patients exhibited bradycardia intraoperatively more than the other groups. we recommend, Dexmedetomidine in the intra-operative phase and lignocaine in the post-operative phase can be an alternative in patients who are poor candidates for post-operative opioids/sedation/contraindicated regional anaesthesia regimes.
围手术期疼痛管理是麻醉医生面临的一项重大挑战。静脉注射利多卡因和右美托咪定已被用于围手术期疼痛管理。
分析术中静脉注射利多卡因/右美托咪定对接受腹腔镜手术患者的疼痛缓解、阿片类药物消耗、围手术期血流动力学及副作用/独特相互作用的影响。
对90例年龄在18 - 60岁的ASA I/II级患者进行了一项前瞻性、干预性、单中心、双盲、随机、活性对照、符合赫尔辛基协议的临床研究。这些患者被整群随机分为L组(2%利多卡因)、D组(右美托咪定)和C组(对照组/安慰剂/0.9%生理盐水)。在术前/术后的预定义时间点记录血流动力学数据。进行术后视觉模拟评分(VAS)和里士满躁动镇静评分监测。
人口统计学参数具有可比性。三组术中芬太尼平均消耗量分别为20.5±20.05微克、26.5±17.57微克和46.83 + 21.31微克(L组、D组、C组;L组与D组比较P值:0.22,L/D组与C组比较:<0.0001)。D组心率和平均动脉压较低(P<0.05)。拔管 - 首次补救镇痛阶段C组和L组相当(59.17±46.224分钟对61.64±53.819分钟),D组明显更长(136.07 + 55.350分钟;P<0.0001)。
右美托咪定和利多卡因均可作为术中疼痛缓解的有用辅助药物。右美托咪定比利多卡因更能延迟首次补救镇痛和总镇痛药物的消耗。右美托咪定组患者术中心动过缓比其他组更常见。我们建议,对于术后阿片类药物/镇静效果不佳或禁忌区域麻醉方案的患者,术中使用右美托咪定,术后使用利多卡因可能是一种替代方案。